US-based global contract development and manufacturing organisation PCI Pharma Services has announced a series of major infrastructure investments forming part of a broader commitment exceeding $1 billion (€925 million) across its US and European operations, substantially deepening its sterile fill-finish and advanced drug delivery capabilities, according to The Canadian Press.

The investment programme is designed to provide seamless support for drug product development and manufacturing, clinical trial supply, and drug-device combination assembly from clinical stages through to commercial launch, underpinned by global capacity, technical expertise, and an industry-leading quality and regulatory track record.

The announcement comes as pharmaceutical manufacturers and their development partners increasingly prioritise US supply chain resilience, with demand for domestically anchored CDMO capabilities accelerating amid ongoing geopolitical and logistical pressures affecting global pharmaceutical ingredient and product supply networks.

PCI Pharma Services specialises in integrated biologic and small molecule therapy development and manufacturing, supporting clients across the full drug development lifecycle. The company's expanded sterile fill-finish capabilities address one of the most technically demanding and capacity-constrained segments of pharmaceutical manufacturing.

Drug-device combination products, which integrate therapeutic agents with delivery mechanisms such as autoinjectors and prefilled syringes, represent a rapidly growing segment of the pharmaceutical market, driven in part by the continued expansion of injectable biologics and GLP-1 therapies requiring sophisticated delivery systems.

The scale of PCI's commitment reflects broader industry momentum toward investment in end-to-end CDMO infrastructure capable of supporting complex, high-value pharmaceutical programmes from early development through commercial-scale production.

Access the full coverage for comprehensive details on PCI Pharma Services' infrastructure investment programme and expanded capabilities.